News | August 26, 2022
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Subscribe To Our Newsletter & Stay Updated
